NVS  Novartis Ag

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

163.89B

Vuru Grade

69.64/100

Current Price

$68.99
+0.82 (+1.20%)

Growth Price

$56.17
Overvalued by 18.58%

Stability Price

$14.61
Overvalued by 78.82%

Company Metrics

  • P/E 24.33
  • P/S 3.26
  • P/B 2.16
  • EPS 2.84
  • Cash ROIC 11.30%
  • Cash Ratio 0.16
  • Dividend 2.72 / 3.99 %
  • Avg. Vol. 2.72M
  • Shares 2.38B
  • Market Cap. 163.89B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Novartis AG (ADR) Stock Was Sold By Options Traders
Frisco Fastball - Nov 29, 2016
In today's session Novartis AG (ADR) (NVS) recorded an unusually high (654) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious NVS decrease.
Novartis AG (ADR) (NYSE:NVS) has been downgraded to Sell in a statement by ... - Breaking Finance News
Novartis Stock Is Worth $90 A Share - Seeking Alpha
Activity Reported By SEC: As Novartis A G (NVS) Market Valuation Declined ...
Chester News - 7 hours ago
Novartis Ag has been the topic of 14 analyst reports since July 28, 2015 according to StockzIntelligence Inc. Chardan Capital Markets initiated Novartis AG (ADR) (NYSE:NVS) on Tuesday, September 20 with “Buy” rating. As per Tuesday, April 12, the ...
What Will Happen to Novartis AG (ADR) Next? The Stock Just Had Huge Bearish ...
Frisco Fastball - Nov 10, 2016
In today's session Novartis AG (ADR) (NVS) recorded an unusually high (588) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious NVS decrease.
Short Interest Reporting: Novartis AG (NYSE:NVS) Can't Be Less Risky. Short ... - Post News
Rating to Follow: Is Argus Research Very Positive For Novartis AG (NYSE:NVS ... - Thorold News
Novartis AG (ADR) (NVS) Acquires Selexys Pharmaceuticals Corp.
Insider Monkey (blog) - Nov 22, 2016
Novartis AG (ADR) (NYSE:NVS) has recently acquired Selexys Pharmaceuticals Corp. after receiving results from the SUSTAIN clinical trial, a Phase II clinical trial evaluating SelG1 for the reduction of vaso-occlusive pain among sickle cell disease (SCD ...
Exclusive: Is Selling 52-Week Stock Like Novartis AG (ADR) a Winning Strategy? - Press Telegraph
Novartis Steps Ahead in Hematology and Inflammatory Therapeutic Areas - TCC
Novartis AG (ADR) (NVS) Multiple Sclerosis Molecule: Ray of Hope
TCC - Sep 19, 2016
Novartis AG (ADR) (NYSE:NVS) investigational molecule for the treatment and management of multiple sclerosis has shown remarkable reduction in the disease progression up to 21%.
Novartis AG (ADR) (NVS) Q3 Earnings: What Leerink Expects
Smаrt Stоck Nеws - Oct 20, 2016
Leerink's 2016 EPS estimate for Novartis stands at $4.8 on revenue of $50.5 billion, compared to consensus of $4.7 and $49 billion, respectively.
Will Novartis AG (ADR) (NVS) Clinch Biosimilar Market by 2020?
TCC - Aug 8, 2016
Novartis AG's (ADR)(NYSE:NVS) biosimilar and generic division, Sandoz is working for the development of novel biosimilars versions of the blockbuster drugs to patch up the revenue loss of its blockbuster drugs' patents.
Will Novartis AG (ADR) (NVS) be Forbidden in Korea after Bribe Charges?
TCC - Aug 16, 2016
Novartis AG (ADR) (NYSE:NVS) is hit by bad news of involvement of its six senior officials under the charges of corruption.
Novartis AG (ADR) (NYSE:NVS) Says A Picture Is Worth A Thousand Words
Market Exclusive - Aug 30, 2016
Through its Canadian unit, Novartis is using images to bring out stories about advanced melanoma. The company says that the idea behind its photo campaign is to spark a conversation around advanced melanoma and to highlight the journey of patients ...
Novartis AG (NYSE:NVS) Fights for Survival after Patent Expiration - TCC
Here's What's Important With The Novartis AG (ADR) (NVS) MS Data - Insider Monkey (blog)
The Biosimilar of Amgen's Enbrel, by Novartis AG (ADR) (NYSE:NVS), has been ...
TCC - Aug 31, 2016
In a latest development, the Food and Drug Administration (FDA) has announced the approval of Novartis AG's (NYSE:NVS) Erelzi, which is a biosimilar version of Amgen's blockbuster drug Enbrel.
Novartis AG (ADR) Enbrel Biosimilar Approved: What's Next for Amgen? - Smаrt Stоck Nеws
Amgen, Inc: How Damaging Will Be Novartis' Enbrel Copy - Bidness ETC